Macquarie Group Shares Jump as Third-Quarter Trading Conditions Improve Across Key Units 
Samsung Electronics Sees Sustained AI-Driven Demand for Memory Chips Into Next Year 
Alphabet Plans Rare 100-Year Sterling Bond to Fund AI Expansion 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Salesforce Workforce Reduction Affects Fewer Than 1,000 Roles Amid Ongoing Restructuring 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
DBS Expects Slight Dip in 2026 Net Profit After Q4 Earnings Miss on Lower Interest Margins 
Taiwan Says Moving 40% of Semiconductor Production to the U.S. Is Impossible 
Canadian Airlines Suspend Cuba Flights Amid Jet Fuel Shortage and U.S. Sanctions 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
Amazon Explores AI Content Marketplace With Media Publishers 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
Trump Administration Plans Chip Tariff Exemptions for Big Tech Amid AI Data Center Push 
TEMPLE CITY, Calif., Nov. 14, 2017 -- Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent Genetics” or the “company”) today announced that its Chairman and Chief Executive Officer Ming Hsieh and its Chief Financial Officer Paul Kim are scheduled to participate in the 29th Annual Piper Jaffray Healthcare Conference on Tuesday, November 28, 2017 at the Lotte New York Palace Hotel in New York, New York.
These representatives of the company will participate in a question-and-answer session with the host analyst beginning at approximately 8:00 a.m. ET.
A live webcast of the question and answer session will be available on the Investor Relations section of the Fulgent Genetics website at ir.fulgentgenetics.com. A replay of the webcast will be accessible at ir.fulgentgenetics.com beginning approximately one hour following the completion of the event.
About Fulgent Genetics
Fulgent Genetics is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes approximately 18,000 single-gene tests and more than 850 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633, [email protected]
